Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Acquires $236,800.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Paul Herendeen purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.68 per share, with a total value of $236,800.00. Following the purchase, the director owned 111,687 shares in the company, valued at $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $22.10 on Thursday. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The business’s 50 day simple moving average is $24.60 and its 200 day simple moving average is $24.04. The company has a market cap of $11.04 billion, a price-to-earnings ratio of -53.90, a PEG ratio of 1.36 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the company earned $0.26 earnings per share. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ELAN. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. KeyCorp lifted their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. TD Cowen boosted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. UBS Group upped their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Morgan Stanley raised their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC increased its stake in Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the last quarter. Sapient Capital LLC boosted its position in shares of Elanco Animal Health by 0.3% during the 2nd quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after acquiring an additional 420 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after acquiring an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC grew its holdings in shares of Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its holdings in shares of Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.